Valuation dashboard for AbCellera Biologics Inc. (ABCL) with P/E N/A, P/B 3.79, EV/EBITDA -21.4 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities.
Analysis Summary
AbCellera Biologics Inc. reported revenue of $75.1M in the most recent fiscal year, growing at a 5-year CAGR of -20.3%.
Trailing-twelve-month margins: gross margin 75.0%, operating margin -340.3%, net margin -248.8%.
At $11.12 (closing price, November 2, 2026), ABCL has negative trailing earnings (P/E not meaningful) and an ROE of -17.49%. Market capitalisation stands at $3.6B.
Balance sheet quality for ABCL: debt-to-equity ratio of 0.15, current ratio of 12.77 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.79 |
| EV / EBITDA | -21.4 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $3.6B | 3.79 | -17.5% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $140.2B | 35.60 | 4.28 | 17.5% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $99.0B | 21.24 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $88.2B | 12.93 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $55.0B | 41.27 | 6.54 | 16.9% |
| 0QNO.L | Lonza Group AG | CHF 43.8B | 5.43 | -1.3% |
Price
| Price | $11.12 (closing price, November 2, 2026) |
| Market Cap | $3.6B |
| Exchange | NASDAQ |
| Country | CA |
Profitability
| Return on Equity | -17.49% |
| Return on Invested Capital | -14.95% |
| Return on Assets | -12.59% |
| Gross Margin | 74.95% |
| Operating Margin | -340.25% |
| Net Margin | -248.83% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of ABCL: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks